Aptamer Group: Turner Pope
has announced an extension to its partnership with Unilever plc (LSE: ULVR). This new phase aims to commence in-vivo efficacy testing ofOptimer® binders as active ingredients in deodorants before the end of 2024.This represents a significant endorsement of the Group’s technology with opportunity to create a long-term interdependent relationship with the consumer goods giant.
Today’s news is also a reminder of the recently appointed CEO’s stated ambition to re-establish focus on asset development and licensing (while seeking to cover Group operating costs through its more predictable but lower value-added fee-for-service (‘FFS’) operations) in expectation of crystallising much higher-value inflection points for shareholders. Beyond Unilever, Aptamer also continues to work with a number of major development partners, including AstraZeneca, NeuroBio and other top-tier pharmaceutical groups, each of which are similarly progressing products that utilise its binders to target global market opportunities.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.